Emcure Pharma's Gujarat Plant Gets FDA All-Clear; Launches New Obesity Drug

• Emcure Pharmaceuticals' Gujarat manufacturing facility received 'No Action Indicated' (NAI) classification from the US FDA after an inspection.
• The FDA inspection, conducted from October 6-10, 2025, at Kadu village, Surendranagar district, found no objectionable conditions.
• The NAI classification confirms compliance with Current Good Manufacturing Practice (cGMP) requirements, with no regulatory action intended.
• Emcure launched Poviztra, a semaglutide injection for chronic weight management, marking its entry into the obesity and metabolic health segment.
• Poviztra, a second brand of Novo Nordisk’s semaglutide, will be available across India starting at ₹8,790 per month for four weekly doses.

Why It Matters: Emcure Pharma secures FDA clearance for its Gujarat plant and expands into the obesity market with Poviztra.